Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality

References

• Abdel-RahmanSMMarcucciKBogeTPotent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafineDrug Metab Dispos199927770510383919
   PubMed Web of Science ®Google Scholar
• AnaniaFARabinLTerbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosisAm J Med2002112741212079721
   PubMed Web of Science ®Google Scholar
• BalfourJAFauldsDTerbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycosesDrugs199243259841372222
   PubMed Web of Science ®Google Scholar
• BeutlerMHartmannKKuhnMTaste disorders and terbinafineBMJ1993307268343667
   PubMed Web of Science ®Google Scholar
• BoldewijnOYOttervangerJPMostartCMHepatitis attributed to the use of terbinafineNed Tijdschr Geneeskd1996140669728668241
   PubMedGoogle Scholar
• BrautigamMNoltingSSchopfRERandomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study GroupBMJ1995311919227580551
   PubMed Web of Science ®Google Scholar
• CarstensJWendelboePSogaardHToxic epidermal necrolysis and erythema multiforme following therapy with terbinafineActa Derm Venereol19947439127817681
   PubMed Web of Science ®Google Scholar
• CribierBJBakshiRTerbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with nondermatophyte infectionsBr J Dermatol20041504142015030322
   PubMed Web of Science ®Google Scholar
• De BackerMDe VroeyCLesaffreETwelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/dayJ Am Acad Dermatol199838S57639594939
   PubMed Web of Science ®Google Scholar
• De DonckerPPharmacokinetics of oral antifungal agentsDermatol Ther199734657
   Google Scholar
• DebruyneDCoquerelAPharmacokinetics of antifungal agents in onychomycosesClin Pharmacokinet2001404417211475469
   PubMed Web of Science ®Google Scholar
• Del RossoJQOral Antifungals: What you should know about drug interactionsPodiatry Today2004116615
   Google Scholar
• DevelouxMGriseofulvin can kill intestinal bacteria whose enzymes help steroid absorptionAnn Dermatol Venereol200112813172511908134
   PubMed Web of Science ®Google Scholar
• DrakeLAScherRKSmithEBEffect of onychomycosis on quality of lifeJ Am Acad Dermatol19983870249591814
   PubMed Web of Science ®Google Scholar
• DrakeLAShearNHArletteJPOral terbinafine in the treatment of toenail onychomycosis: North American multicenter trialJ Am Acad Dermatol19973774059366820
   PubMed Web of Science ®Google Scholar
• DuxburyAJOliverRJPembertonMNPersistent impairment of taste associated with terbinafineBr Dent J2000188295610800234
   PubMed Web of Science ®Google Scholar
• ElewskiBSmithSThe safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positiveCutis20016823911499331
   PubMedGoogle Scholar
• EvansEGSigurgeirssonBDouble blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study GroupBMJ19993181031510205099
   PubMed Web of Science ®Google Scholar
• FriisHAndreasenPBDrug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987J Intern Med199223213381506809
   PubMed Web of Science ®Google Scholar
• Garcia RodriguezLADuqueACastellsagueJA cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugsBr J Clin Pharmacol1999488475210594489
   PubMed Web of Science ®Google Scholar
• GhannoumMAChaturvediVEspinel-IngroffAIntra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytesJ Clin Microbiol2004422977915243047
   PubMed Web of Science ®Google Scholar
• GoodfieldMJAndrewLEvansEGShort term treatment of dermatophyte onychomycosis with terbinafineBr Med Journal1992304115141392793
   PubMed Web of Science ®Google Scholar
• GuptaAKdel RossoJQLyndeCWHepatitis associated with terbinafine therapy: three case reports and a review of the literatureClin Exp Dermatol1998236479692307
   PubMed Web of Science ®Google Scholar
• GuptaAKJainHCLyndeCWPrevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada–a multicenter survey of 2001 patientsInt J Dermatol19973678379372358
   PubMed Web of Science ®Google Scholar
• GuptaAKRyderJETavakkolAThe use of terbinafine in the treatment of onychomycosis in adults and special patient populations: a review of the evidenceJ Drugs Dermatol20054299305
   Google Scholar
• GuptaAKShearNHA risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosisDrug Safety20002215210647972
   PubMed Web of Science ®Google Scholar
• HallAPTateBAcute generalized exanthematous pustulosis associated with oral terbinafineAustralasian J Dermatol200041425
   PubMedGoogle Scholar
• HallMMonkaCKruppPSafety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patientsArch Dermatol19971331213199382559
   PubMed Web of Science ®Google Scholar
• HanekeETauschIBrautigamMShort-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study GroupJ Am Acad Dermatol1995327277822520
   PubMed Web of Science ®Google Scholar
• HavuVHeikkilaHKuokkanenKA double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosisBr J Dermatol20001429710210651701
   PubMed Web of Science ®Google Scholar
• HayRJRisk/benefit ratio of modern antifungal therapy: focus on hepatic reactionsJ Am Acad Dermatol199329S5048315062
   PubMed Web of Science ®Google Scholar
• HeikkilaHStubbSThe prevalence of onychomycosis in FinlandBr J Dermatol19951336997038555019
   PubMed Web of Science ®Google Scholar
• HerranzPGarciaJDe LucasRToenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafineBr J Dermatol1997137577809390334
   PubMed Web of Science ®Google Scholar
• HofmannHBrautigamMWeidingerGTreatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study GroupArch Dermatol1995131919227632064
   PubMedGoogle Scholar
• KatzHIDrug interactions of the newer oral antifungal agentsBr J Dermatol1999141263210730911
   PubMed Web of Science ®Google Scholar
• LeydenJPharmacokinetics and pharmacology of terbinafine and itraconazoleJ Am Acad Dermatol199838S42479594936
   PubMed Web of Science ®Google Scholar
• LinCLimJDi GioreCComparative bioavailability of a microsize and ultramicrosize griseofulvin formulation in manJ Int Med Res19821027477117684
   PubMed Web of Science ®Google Scholar
• MallatAZafraniESMetreauJMTerbinafine-induced prolonged cholestasis with reduction of interlobular bile ductsDig Dis Sci199742148689246051
   PubMed Web of Science ®Google Scholar
• MedwatchSummary Of Safety-Related Drug Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)2001Washington, DC, USAFood and Drug Administration
   Google Scholar
• MeinhofWKinetics and spectrum of activity of oral antifungals; the therapeutic implicationsJ Am Acad Dermatol199329S37418315060
   PubMed Web of Science ®Google Scholar
• NandwaniRParnellAYouleMUse of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasisBr J Dermatol19961342248763464
   PubMed Web of Science ®Google Scholar
• NedelmanJCramerJARobbinsBThe effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjectsBiopharm Drug Dispos199718127389099449
   PubMed Web of Science ®Google Scholar
• O'SullivanDPTerbinafine: tolerability in general medical practiceBr J Dermatol199914121510730910
   PubMed Web of Science ®Google Scholar
• O'SullivanDPNeedhamCABangsAPostmarketing surveillance of oral terbinafine in the UK: report of a large cohort studyBr J Clin Pharmacol199642559658951186
   PubMed Web of Science ®Google Scholar
• ParkYMKimJWKimCWAcute generalized exanthematous pustulosis induced by itraconazoleAm Acad Dermatol1997367946
   PubMed Web of Science ®Google Scholar
• PollakRBillsteinSASafety of oral terbinafine for toenail onychomycosisJ Am Podiatr Med Assoc199787565709425805
   PubMed Web of Science ®Google Scholar
• PollakRAHarklessLBJenningsMBTerbinafine: Reality versus perception concerning liver functionAm Podiatric Med Assoc2004Boston, USA International Annual Meeting, August 2004
   Google Scholar
• RichPHouptKRLa MarcaASafety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetesCutis200168152211499330
   PubMedGoogle Scholar
• ScherRKOnychomycosis: therapeutic updateJ Am Acad Dermatol199940S21610367912
   PubMed Web of Science ®Google Scholar
• ShapiroLEShearNHDrug interactions: Proteins, pumps, and P-450sJ Am Acad Dermatol20024746784 quiz 485–812271287
   PubMed Web of Science ®Google Scholar
• ShearNDrakeLGuptaAKThe implications and management of drug interactions with itraconazole, fluconazole and terbinafineDermatology200020119620311096189
   PubMed Web of Science ®Google Scholar
• ShiloahEHorowizMZeclerETerbinafine-induced cholestatic liver injuryHarefuah19971331112 80–19332048
   PubMedGoogle Scholar
• SkorepovaMRisk of liver damage casued by modern systemic antimycoticsCes-lov Derm2004795961
   Google Scholar
• SmithEBSteinLFFivensonDPThe safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomychosis of the feetInt J Dermatol2000398596411123451
   PubMed Web of Science ®Google Scholar
• SmithSHouptKRichPShort-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patientsCutis20016830911499332
   PubMedGoogle Scholar
• TailorSAGuptaAKWalkerSEPeripheral edema due to nifedipine-itraconazole interaction: a case reportArch Dermatol199613235028607648
   PubMed Web of Science ®Google Scholar
• ToddPHalpernSMunroDDOral terbinafine and erythema multiformeClin Exp Dermatol19952024787671425
   PubMed Web of Science ®Google Scholar
• van 't WoutJWHerrmannWAde VriesRATerbinafine-associated hepatic injuryJ Hepatol199421115177963410
   PubMed Web of Science ®Google Scholar
• VenkatakrishnanKvon MoltkeLLGreenblattDJEffects of the antifungal agents on oxidative drug metabolism: clinical relevanceClin Pharmacokinet2000381118010709776
   PubMed Web of Science ®Google Scholar
• VickersAESinclairJRZollingerMMultiple cytochrome P-450sb involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactionsDrug Metab Dispos19992710293810460803
   PubMed Web of Science ®Google Scholar
• VivasSRodriguezMPalacioMAAcute hepatitis associated with terbinafineGastroenterol Hepatol19972045689445740
   PubMedGoogle Scholar
• WatsonAMarleyJEllisDTerbinafine in onychomycosis of the toenail: a novel treatment protocolJ Am Acad Dermatol19953377597593777
   PubMed Web of Science ®Google Scholar